Skip to Main Content

Learn more about NeuroQuant 3.0 as a diagnostic tool for Alzheimer’s disease at AAIC 2019


2 mins

The team is pleased to attend the Alzheimer’s Association International Conference (AAIC) and share how NeuroQuant, an FDA cleared brain imaging analysis software, is being used to measure brain atrophy in Alzheimer’s disease patients. With NeuroQuant’s automated quantification reports, radiologists can provide a fast and uniform reading, and patients and their referring physicians receive a tangible report they can understand to inform treatment and planning.

Find us at booth #527 at the Los Angeles Convention Center, July 14th-17th. 

Schedule a time to meet with us!

With 1 in 5 Alzheimer’s cases being misdiagnosed (Eli Lilly), it is important that reproducible and objective brain volumetric data be a part of the physician’s analysis. This is why we are constantly improving our products to offer the most accurate quantitative measurements that physicians can incorporate for supported diagnoses. NeuroQuant 3.0 brings improved segmentation accuracy, robust reports, and a change visualization overlay for monitoring disease progression. Other improvements include:

  1. Enhanced segmentation accuracy, an improvement that only we are able to provide through our many partnerships with leading scanner manufacturers. 
  2. The change visualization output provides a heat map overlay which allows users to easily visualize volumetric change from a prior scan to a current scan directly on the T1 weighted image in their DICOM viewer. This includes anything from ventricle expansion to tissue swelling and atrophy.
  3. Improved reports include streamlined results, and new structures quantified

Through a partnership with HealthLytix, we will be showcasing IntegratedRiskTM which combines HealthLytix’s genetic data with NeuroQuant’s automated brain volumetrics to create a powerful tool capable of determining one’s likelihood of developing late-onset Alzheimer’s. This movement towards preventive healthcare redefines how clinicians monitor and track patient’s disease progression.

You can learn more about adding NeuroQuant to genetic data to improve risk prediction for Alzheimer’s disease an oral session presented by HealthLytix at AAIC.

Integrating Genetics and Brain Imaging to Improve Alzheimer’s Disease Risk Prediction
Presented by: Chun Fan, MD, MSc, PhD, Chief Data Scientist, HealthLytix
Date: Thursday, July 18, 2019
Time: 12:15 to 12:30 p.m.
Where: 515AB at the Los Angeles Convention Center.

Our team will be at booth #527 to answer your questions and provide a more in-depth look at the great enhancements in store for users. CEO, Chris Airriess, will be attending alongside our VP of Sales, Amy Verrinder and senior account manager, Kolby Pronenko, and clinical specialist, Micki Maes. They will be joined by Brittany Hunt, associate director of business development for HealthLytix. 

We hope you join us as we lead the way in utilizing AI to revolutionize patient care!